MDR

Congratulations to Dr Matt Burman on his latest paper with the TBNet group

Congratulations to Matt Burman on his latest paper as part of the European collective TBNet. The study explored second line drugs used to treat multidrug-resistant (MDR)- tuberculosis (TB) and their effect on QT interval. Fluoroquinolones and, possibly, clofazimine can prolong the QTc, as do bedaquiline and delamanid. A QTc >500 ms is considered a risk factor … Continue reading →